The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters
Crossref DOI link: https://doi.org/10.1007/s00417-014-2641-3
Published Online: 2014-04-29
Published Print: 2014-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Elshout, Mari
van der Reis, Margriet I.
Webers, Carroll A. B.
Schouten, Jan S. A. G.
Text and Data Mining valid from 2014-04-29